please refer to pages 2 and 3 for the stakeholder list cc
TRANSCRIPT
1 | P a g e
DATE: August 28, 2015 TO: Please refer to pages 2 and 3 for the Stakeholder List CC: Dr. James Silvius, Chair of Provincial Drugs and Therapeutics Committee
[Provincial Drugs and Therapeutics Committee membership] Jeremy Slobodan, Director, Drug Stewardship, Procurement & Inventory, Pharmacy Services Dr. Erwin Friesen, Manager, Therapeutics, Pharmacy Services Tracey Simpson, Provincial Manager of Procurement, Inventory and Service Performance, Pharmacy Services
FROM: Rita Muzyka, Drug Utilization Evaluation Pharmacist, Pharmacy Services RE: Olmesartan (Olmetec
®) Formulary Evaluation
Olmesartan has been requested for addition to the Alberta Health Services (AHS) Provincial Drug Formulary. A formulary evaluation of the efficacy, safety, and cost-effectiveness of olmesartan is enclosed. Olmesartan will be discussed at an upcoming Provincial Drugs and Therapeutics Committee (DTC) meeting. To ensure that all issues have been addressed prior to this meeting, please review the formulary evaluation and then provide your feedback by using the Olmesartan Stakeholder Feedback Survey available online at: https://survey.albertahealthservices.ca/TakeSurvey.aspx?SurveyID=n6237p3M The attached formulary evaluation has been distributed to the stakeholders listed on pages 2 and 3 of the cover letter via their AHS email addresses (unless otherwise known). Please review the stakeholder list and then cascade this email on to all relevant individuals within your organizational structure/ program to enable additional stakeholders to participate in this survey. If you are aware of any other relevant stakeholders, please also forward this email to them. All stakeholder feedback is important and will be collated and presented to the Provincial DTC for consideration of the formulary status of olmesartan. While stakeholder name, division/department and conflict of interest disclosure is required, this information will only be published in aggregate and responses will not be attributed to individuals. Incomplete survey responses or feedback provided via email cannot be tabulated at this time. The deadline for completing the Stakeholder Feedback Survey is Friday, September 25, 2015. This is your opportunity to support the proposed formulary recommendation or express your concern(s) so please ensure that your response is received by the deadline provided. If no response is received, the next steps of the formulary approval process will still proceed. Thank you in advance for your feedback and time. Note: If a paper copy of this survey is required, please email [email protected] or phone 780-735-5723. Enclosure: Olmesartan (Olmetec
®) Formulary Evaluation
2 | P a g e
STAKEHOLDER LIST Please review the stakeholder list and then cascade this email on to all relevant individuals within your organizational structure/program to enable additional stakeholders to participate in this survey. Medical Stakeholders Dr. Blair O’Neill, Edmonton Zone Division Chief, Cardiology Dr. David Johnstone, Mazankowski Alberta Heart Institute Clinical Director, Cardiology Dr. Daniel Kim, UAH/Mazankowski Alberta Heart Institute Medical Director, Advanced Heart Failure and Transplantation Dr. Randy Williams, RAH Site Chief, Cardiology Dr. Zaheer Lakhani, SCH Site Chief, Cardiology Dr. Tim Muzyka, MCH Site Chief, Cardiology Dr. Ken Woo, GNCH Site Chief, Cardiology Dr. Dylan Taylor, UAH/MAHI Site Chief, Cardiology Dr. Todd Anderson, Calgary Zone Clinical Department Chief, Cardiac Sciences and Director of the Libin Cardiovascular
Institute of Alberta Dr. Ed O’Brien, Calgary Zone Section Chief, Cardiology Dr. David Goodhart, FMC Site Leader, Cardiology Dr. Hamid Banijamali, PLC Site Leader, Cardiology Dr. Sandeep Aggarwal, RGH Site Leader, Cardiology Dr. Regina Donnelly, Central Zone Chief, Cardiology Dr. Kym Jim, Central Zone Clinical Department Head, Internal Medicine Dr. Brennan Walters, MCH Medicine Site Chief, Medicine Dr. John Cesarz, SCH Site Chief, Medicine Dr. John Bradley, GNCH Site Chief, Medicine Dr. Stuart Rosser, RAH Site Chief, Medicine Dr. Kelly Zarnke, Calgary Division Chief, General Internal Medicine Dr. Callisto Tarukandirwa, Central Zone Chief, General Internal Medicine Dr. Sandra Ann Colbourne, Edmonton Zone, General Internal Medicine Dr. Michael Chan, Edmonton Zone, General Internal Medicine Dr. Godwin Mouton, Redwater Health Centre, Site Medical Lead Dr. Anne Bowland, MCH Site Chief, Family Medicine Dr. Irene Colliton, GNCH Site Chief, Family Medicine Dr. Anton Du Toit, LCH Site Chief, Family Medicine Dr. Nigel Flook, UAH Site Chief, Family Medicine Dr. Allan McDonald, SCH Site Chief, Family Medicine Dr. Jennifer Minsos, RAH Site Chief, Family Medicine Dr. Melanie Currie, WestView Health Centre Site Chief, Family Medicine Dr. Mike Spady, Calgary Zone Department Head, Family Medicine Dr. Bahigi Fyith, Calgary Zone Medical/Clinical Lead, Family Medicine
Zone Medical Directors Medical Director, North Zone Dr. Kevin Worry Medical Director, Central Zone Dr. Evan Lundall Medical Director, South Zone Dr. Vanessa Maclean Senior Medical Director/ZMMC Co-chair, Cancer care Dr. Paul Grundy Senior VP of Medicine and Chief Medical Officer, Covenant Dr. Jeff Robinson Medical Director, Poison and Drug Information Service (PADIS) Dr. Mark Yarema Facilities Medical Director - Correctional Health Services Dr. Keith Courtney
3 | P a g e
Zone Medical Advisory Council (ZMAC) Chairs ZMAC Chair, South zone Dr. Donald Davis ZMAC Chair, Central zone Dr. Art Jaroni ZMAC Chair, Edmonton zone Dr. Charles Harley ZMAC interim Chair, North zone Dr. Gerhard Benade ZMAC Chair, Calgary zone Dr. Roger Galbraith
Pharmacy Stakeholders Pharmacy Leadership Team Pharmacy Clinical Practice Leaders Drug Utilization and Stewardship Pharmacists
Provincial Medication Management Committee (PMMC) / Zone Medication Management Committee (ZMMC) Stakeholders PMMC co-Chair and Vice President, Pharmacy Services Karen Horon PMMC co-Chair Carolyn Hoffman ZMMC co-Chair and Pharmacy Executive Director, Calgary zone Lori Romonko-Slack ZMMC co-Chair, Calgary zone Margaret Fullerton ZMMC co-Chair and Pharmacy Director, Cancer Services Carole Chambers ZMMC co-Chair and Pharmacy Executive Director, Edmonton zone Deb Van Haaften ZMMC co-Chair, Edmonton zone Carol Manson-McLeod ZMMC co-Chair and Pharmacy Director, North zone Guy Lacombe ZMMC co-Chair, North zone Rosemary Van Herk-Auger ZMMC co-Chair and Pharmacy Director, South zone - acting Ryan Abell ZMMC co-Chair, South zone Dr. Vince DiNinno ZMMC co-Chair and Pharmacy Director, Central zone Ryan Abell ZMMC co-Chair, Central zone Dr. Steven Turner Covenant Health Medication Management Committee co-Chair Gordon Stewart Covenant Health Medication Management Committee co-Chair Theresa Imlah
Executive Stakeholders Chief Program Officer, Clinical Support Services Mauro Chies Chief Clinical Officer/ VP Quality Dr. Verna Yiu Interim President & CEO Zone & Health Operations and VP & Chief Health Operations Officer, Central and Southern Alberta Brenda Huband
Medical Director, Central and Southern Alberta Dr. Francois Belanger
VP & Medical Director, Northern Alberta Dr. David Mador Senior Vice-President, Cancer care: Dr. Paul Grundy Senior Vice-President, Central zone: Kerry Bales Senior Vice-President, North zone: Shelly Pusch Senior Vice-President, South zone: Sean Chilton
